Current Clinical Trials
LSO has completed Aptocine treatment in a Phase 3 trial in hepatocellular carcinoma and in a Phase 3 trial in colorectal cancer metastatic to the liver. LSO has completed treatment in Phase 1 and Phase 2 clinical trials in benign prostatic hyperplasia (BPH).
Light Sciences (now LSO) was founded in 1994 to develop a commercially viable light-activated drug product to treat patients with solid tumor cancers. LSO has built a strong development organization with an efficient team overseeing engineering, clinical trials, manufacturing, and regulatory/legal affairs. The company is developing Aptocine, a light-activated drug with a small, single-use, disposable drug activator that is designed for easy use by physicians to provide tolerable, effective, and repeatable treatments to patients.
The company has raised more than $165 million in equity and debt financing since inception.